SCHEMBL30749142

SCHEMBL30749142

O=C1CCc2cnc(Cl)nc2N1c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
LMNA P02545 2/20 0.45
MGLL Q99685 1/20 0.43
KMT2A Q03164 3/20 0.40
GFER P55789 1/20 0.40
PLCG1 P19174 1/20 0.40
POLB P06746 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 2/20 0.39
USP2 O75604 1/20 0.39
ALOX15 P16050 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PIN1 Q13526 3/20 0.38
HPGD P15428 1/20 0.38
MMP2 P08253 2/20 0.36
MMP3 P08254 2/20 0.36
MMP9 P14780 2/20 0.36
MMP13 P45452 2/20 0.36
CTSG P08311 1/20 0.36
CMA1 P23946 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748879 0.89 ALDH1A1 (0.44) ALDH1A1LMNAMGLLKMT2AGFER
SCHEMBL30748892 0.84 MGLL (0.41) ALDH1A1LMNAMGLLKMT2AGFER
SCHEMBL30748788 0.83 MGLL (0.40) ALDH1A1LMNAMGLLKMT2AGFER
SCHEMBL30748992 0.83 KMT2A (0.43) ALDH1A1LMNAMGLLKMT2AGFER
SCHEMBL17281692 0.76 MGLL (0.65) ALDH1A1LMNAMGLLKMT2AGFER
SCHEMBL30748809 0.74 CCNE1 (0.45) ALDH1A1LMNAMGLLPLCG1MAPT
SCHEMBL30748753 0.70 ALDH1A1 (0.44) ALDH1A1LMNAKMT2APOLBSMN1; SMN2
SCHEMBL4686776 0.70 FGFR4 (0.47) POLBMAPTTDP1CTSGCMA1
SCHEMBL32668241 0.69 POLB (0.70) ALDH1A1LMNAMGLLKMT2APLCG1
SCHEMBL3587601 0.68 LMNA (0.87) ALDH1A1LMNAMGLLKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT ALDH1A1 256/4885LMNA 128/4885MGLL 2683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.